Page 203 - Haematologica Vol. 109 - July 2024

ARTICLE - FLT3L promotes osteolysis in multiple myeloma
D. Shin et al.
es of FLT3L/FLT3 inhibitors over DKK1 inhibitors should be further investigated in a large cohort of patients.
We enrolled patients diagnosed with MM from 2004 to 2012, a period in which the ISS still had to gain popularity among clinicians, so we could not collect information from the ISS in our cohort. Nevertheless, we think that our information aligns well, not with the ISS, but with the old Durie-Salmon staging system, since the ISS does not include information about bone osteolysis, while the Durie-Salmon staging sys- tem does. Enrichment of patients having high expression of both FLT3L and DKK1 in the HY subtype of MM suggested that FLT3L-mediated bone osteolysis might be prominent in the HY subtype. Accordingly, therapies to inhibit the FLT3L-mediated bone osteolysis might be most effective for patients in the HY subtype. These subtype-associated predictions should be verified in plasma cells derived from a large cohort of patients with MM.
Disclosures
No conflicts of interest to disclose.
Contributions
YK, SSY and DH designed and supervised the studies. DS re- cruited, treated, and followed the enrolled patients together with SSY. DS collected BM-derived plasma cells from patients.
References
1. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101(2):237-244.
2. Sneyd MJ, Gray AR, Morison IM. Trends in survival from myeloma, 1990-2015: a competing risks analysis. BMC Cancer. 2021;21(1):821.
3. Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195-200.
4. Denaro V, Denaro L, Albo E, Papapietro N, Piccioli A, Di Martino A. Surgical management of spinal fractures and neurological involvement in patients with myeloma. Injury.
2016;47(Suppl 4):S49-S53.
5. Body JJ, Pereira J, Sleeboom H, et al. Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ. 2016;17(6):711-721.
6. Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real- world data. J Bone Oncol. 2019;14:100215.
7. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
8. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with
DS, DK, CL and KSA measured cytokines with DK, CL and KSA. MJK performed most of the in vitro experiments. EJ, BCL and DK performed the TRAP assay. SC analyzed transcriptome database. YK, DS, DH and SSY wrote the draft of the manu- script and all authors revised the final version for publication.
Acknowledgments
We are grateful to the patients and their families for their participation in this study. The authors would like to thank the members of Genome Maintenance at Sookmyung Women’s University, Seoul, South Korea, for their invaluable comments and suggestions.
Funding
This work was supported by the National Research Founda- tion of Korea (NRF) Grant funded by the Korean Government (MSIP) (NRF-2023R1A2C3007266, NRF-2021R1A6A1A03038890 to YK and RS-2023-00239194 to MJK). This research was partially supported by Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (N. 2021R1A6C101A564).
Data-sharing statement
All the original data, reagents and protocols are available upon request.
bisphosphonate and thalidomide treatment. Clin Cancer Res.
2013;19(21):6030-6038.
9. Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S.
Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm. 2017;2017:1852517.
10. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7.
11. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;17(6):1278-1286.
12. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-2494.
13. Dun X, Jiang H, Zou J, et al. Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma. Mol Cancer. 2010;9:247.
14. Yuan Y, Guo M, Gu C, Yang Y. The role of Wnt/b-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). Am J Transl Res. 2021;13(9):9932-9949.
15. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751-764.
16. van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33(5):1063-1075.
17. Politou MC, Heath DJ, Rahemtulla A, et al. Serum
Haematologica | 109 July 2024
2217